Evidence map›Paper›PMID 34324172›Full record

ArticleDrug safety2021

Authors' Reply to Braillon and Martin's Comment on "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)".

Priya Bahri, Daniel R Morales, Adrien Inoubli, Jean-Michel Dogné, Sabine M J M Straus

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Priya BahriEuropean Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands. priya.bahri@ema.europa.eu.
Daniel R MoralesDivision of Population Health Sciences, University of Dundee, Dundee, UK.
Adrien InoubliAgence Nationale de Sécurité du Médicament et des Produits de Santé, Paris, France.
Jean-Michel DognéFederaal Agentschap voor Geneesmiddelen en Gezondheidsproducten-Agence Fédérale des Médicaments et des Produits de Santé, Bruxelles, Belgium.
Sabine M J M StrausCollege ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands.
European Medicines Agency · NLAgence Nationale de Sécurité du Médicament et des Produits de Santé · FRMedicines Evaluation Board · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Health PersonnelValproic AcidDelivery of Health CareHumansValproic Acid

Identifiers

PMID34324172
OpenAlexW3183345246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.